![](/wp-content/uploads/2020/05/Xeris-Zealand-Announcement.png)
$599
Zealand Q1 ’20 Earnings Update; Xeris Partners with Clinigen
Two diabetes-related news items have ben observed: Zealand hosted its Q1 ’20 earnings call and Xeris announced it has entered into an agreement with Clinigen for ex-US Gvoke distribution. Importantly, Zealand disclosed BI is now pursuing its GLP-1/GCG dual agonist (BI 456906) for NASH. Below, FENIX provides highlights and insights from the respective news items.